Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 4, 2011, Pages 1029-1036

  Shaffer, Richard ^a,b   Pickles, Tom ^a   Lee, Richard ^a   Moiseenko, Vitali ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

Alpha beta ratio; Brachytherapy; Fractionation; Prostate cancer; Radiotherapy

Indexed keywords

ALPHA-BETA; ANDROGEN DEPRIVATION THERAPY; BEST ESTIMATES; BIOCHEMICAL FAILURE; BRACHYTHERAPY; CONFIDENCE INTERVAL; CONFIDENCE LIMIT; EXTERNAL BEAM RADIOTHERAPY; EXTREME VALUE; GLEASON SCORES; LINEAR QUADRATIC; MAXIMUM LIKELIHOOD ANALYSIS; NORMAL TISSUE; PROFILE LIKELIHOOD; PROSTATE BRACHYTHERAPY; PROSTATE CANCER; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIOBIOLOGICAL PARAMETERS; RELATIVE BIOLOGICAL EFFECTIVENESS; VARYING PARAMETERS;

MAXIMUM LIKELIHOOD ESTIMATION; ONCOLOGY; RADIOTHERAPY; RISK PERCEPTION; SENSITIVITY ANALYSIS; STATISTICAL METHODS; UNCERTAINTY ANALYSIS;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

ADULT; ALPHA BETA RATIO; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BOOTSTRAPPING; BRACHYTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOLOGICAL PARAMETERS;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; ORGANS AT RISK; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RELATIVE BIOLOGICAL EFFECTIVENESS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; UNCERTAINTY;

EID: 79951957842     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.12.058     Document Type: Article

References (50)

1. D.J. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101 (Pubitemid 29144800)
2. D.J. Brenner, A.A. Martinez, and G.K. Edmundson Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13 (Pubitemid 34041562)
3. C.R. King, and J.F. Fowler A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low Int J Radiat Oncol Biol Phys 51 2001 213 214 (Pubitemid 32758881)
4. W.D. D'Souza, and H.D. Thames Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51 2001 1 3 (Pubitemid 32758853)
5. S.M. Bentzen, and M.A. Ritter The alpha/beta ratio for prostate cancer: What is it, really? Radiother Oncol 76 2005 1 3 (Pubitemid 41096507)
6. E.F. Miles, and W.R. Lee Hypofractionation for prostate cancer: A critical review Semin Radiat Oncol 18 2008 41 47 (Pubitemid 350235955)
7. P.E. Lindsay, V.V. Moiseenko, and J. Van Dyk The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer Phys Med Biol 48 2003 507 522 (Pubitemid 36322042)
8. T. Pickles British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy Int J Radiat Oncol Biol Phys 64 2006 1355 1359
9. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology - prostate cancer (v2) 2009 NCCN Fort Washington, PA
10. W.J. Morris, M. Keyes, and D. Palma Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer Urology 73 2009 860 865 discussion 865-667
11. J.C. Blasko, T. Mate, and J.E. Sylvester Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes Semin Radiat Oncol 12 2002 81 94 (Pubitemid 34094799)
12. T. Pickles, M. Keyes, and W.J. Morris Brachytherapy or conformal external radiotherapy for prostate cancer: A single-institution matched-pair analysis Int J Radiat Oncol Biol Phys 76 2010 43 49
13. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference Int J Radiat Oncol Biol Phys 65 2006 965 974
14. H.D. Thames Jr., M.E. Rozell, and S.L. Tucker Direct analysis of quantal radiation response data Int J Radiat Biol Relat Stud Phys Chem Med 49 1986 999 1009 (Pubitemid 16036970)
15. D.R. Cox The analysis of binary data 1977 Chapman and Hall London
16. S.A. Roberts, and J.H. Hendry The delay before onset of accelerated tumour cell repopulation during radiotherapy: A direct maximum-likelihood analysis of a collection of worldwide tumour-control data Radiother Oncol 29 1993 69 74 (Pubitemid 23336821)
17. M.J. Rivard, B.M. Coursey, and L.A. DeWerd Update of AAPM task group no. 43 report: A revised AAPM protocol for brachytherapy dose calculations Med Phys 31 2004 633 674 (Pubitemid 38381028)
18. C.C. Ling, W.X. Li, and L.L. Anderson The relative biological effectiveness of I-125 and Pd-103 Int J Radiat Oncol Biol Phys 32 1995 373 378
19. Dale RG, Jones B. Is the alpha/beta for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021-1031. Int J Radiat Oncol Biol Phys 2002;52:1427-1428; author reply 1428.
20. J.Z. Wang, M. Guerrero, and X.A. Li How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 55 2003 194 203 (Pubitemid 36020360)
21. K. Hausterman, and J.F. Fowler A comment on proliferation rates in human prostate cancer Int J Radiat Oncol Biol Phys 48 2000 303 (Pubitemid 30488242)
22. K.M. Haustermans, I. Hofland, and H. Van Poppel Cell kinetic measurements in prostate cancer Int J Radiat Oncol Biol Phys 37 1997 1067 1070 (Pubitemid 27237722)
23. G. Iwi, R.K. Millard, and A.M. Palmer Bootstrap resampling: A powerful method of assessing confidence intervals for doses from experimental data Phys Med Biol 44 1999 N55 N62
24. L. Potters, Y. Cao, and E. Calugaru A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 50 2001 605 614 (Pubitemid 32519593)
25. R.G. Stock, N.N. Stone, and A. Tabert A dose-response study for I-125 prostate implants Int J Radiat Oncol Biol Phys 41 1998 101 108 (Pubitemid 28211308)
26. M.J. Zelefsky, D.A. Kuban, and L.B. Levy Multi-institutional analysis of long-term outcome for Stages T1-T2 prostate cancer treated with permanent seed implantation Int J Radiat Oncol Biol Phys 67 2007 327 333 (Pubitemid 46108308)
27. J. Fowler, R. Chappell, and M. Ritter Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031 (Pubitemid 32594841)
28. G.S. Merrick, W.M. Butler, and R.W. Galbreath Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer Int J Radiat Oncol Biol Phys 51 2001 41 48 (Pubitemid 32758859)
29. L. Potters, C. Morgenstern, and E. Calugaru 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer J Urol 173 2005 1562 1566 (Pubitemid 40524771)
30. M.J. Zelefsky, Y. Yamada, and G.N. Cohen Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 67 2007 65 70 (Pubitemid 44959499)
31. T. Pickles Prostate Cohort Outcomes Initiative. Verification of the Kattan prostogram in Canadian practice Radiother Oncol 69 2003 s32 s33
32. O. Cahlon, M.J. Zelefsky, and A. Shippy Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2008 330 337
33. M. van Herk, P. Remeijer, and C. Rasch The probability of correct target dosage: Dose-population histograms for deriving treatment margins in radiotherapy Int J Radiat Oncol Biol Phys 47 2000 1121 1135 (Pubitemid 30345614)
34. M. Zhang, V. Moiseenko, and M. Liu Internal fiducial markers can assist dose escalation in treatment of prostate cancer: Result of organ motion simulations Phys Med Biol 51 2006 269 285 (Pubitemid 43231971)
35. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer J Clin Oncol 17 1999 168 172 (Pubitemid 29022390)
36. A. Haworth, M. Ebert, and D. Waterhouse Assessment of i-125 prostate implants by tumor bioeffect Int J Radiat Oncol Biol Phys 59 2004 1405 1413 (Pubitemid 38954062)
37. A.E. Nahum, B. Movsas, and E.M. Horwitz Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio Int J Radiat Oncol Biol Phys 57 2003 391 401 (Pubitemid 37040935)
38. S.G. Williams, T. Pickles, and L. Kestin Androgen deprivation therapy plus hypofractionated prostate Radiotherapy - are we castrating the radiobiological advantage? Int J Radiat Oncol Biol Phys 72 2008 S73
39. Ontario clinical oncology group; PROFIT - Prostate Fractionated Irradiation Trial. Available at http://clinicaltrials.gov/show/NCT00304759. Bethesda, MD: National Library of Medicine; 2000-. Cited April 19, 2009.
40. Radiation Therapy Oncology Group. Radiation therapy in treating patients with Stage II prostate cancer. Available at http://clinicaltrials.gov/show/ NCT00331773. Bethesda, MD: National Library of Medicine; 2000-. Cited April 19, 2009.
41. Institute of Cancer Research, United Kingdom. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer: CHHIP. Available at http://clinicaltrials.gov/ct/show/NCT00392535. Bethesda, MD: National Library of Medicine; 2000-. Cited April 19, 2009.
42. A. Pollack, A.L. Hanlon, and E.M. Horwitz Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial Int J Radiat Oncol Biol Phys 64 2006 518 526 (Pubitemid 43083441)
43. D.E. Lea Actions of radiation on living cells 1946 Cambridge University Press London
44. D.E. Lea, and D.G. Catcheside The mechanism of the induction by radiation of chromosome aberrations in Tradescantia J Genet 44 1942 216 245
45. B.G. Douglas, and J.F. Fowler The effect of multiple small doses of x rays on skin reactions in the mouse and a basic interpretation Radiat Res 66 1976 401 426
46. V. Antipas, R.G. Dale, and I.P. Coles A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd Phys Med Biol 46 2001 2557 2569 (Pubitemid 32982395)
47. Dale RG, Jones B. Is the alpha/beta for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021-1031. Int J Radiat Oncol Biol Phys 2002;52:1427-1428.
48. D.L. Zellmer, J.D. Shadley, and M.T. Gillin Comparisons of measured biological response and predictions from microdosimetric data applicable to brachytherapy Radiat Prot Dosimetry 52 1994 395 403 (Pubitemid 24120368)
49. A.M. Kellerer, and H.H. Rossi The theory of dual radiation action Curr Topics Radiat Res Q 8 1972 85
50. R.G. Dale The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br J Radiol 58 1985 515 528 (Pubitemid 15018411)